Microdeletions of chromosomal region 2q23.1 that disrupt MBD5 (methyl-CpG-binding domain protein 5) contribute to a spectrum of neurodevelopmental phenotypes; however, the impact of this locus on human psychopathology has not been fully explored. To characterize the structural variation landscape of MBD5 disruptions and the associated human psychopathology, 22 individuals with genomic disruption of MBD5 (translocation, point mutation and deletion) were identified through whole-genome sequencing or cytogenomic microarray at 11 molecular diagnostic centers. The genomic impact ranged from a single base pair to 5.4 Mb. Parents were available for 11 cases, all of which confirmed that the rearrangement arose de novo. Phenotypes were largely indistinguishable between patients with full-segment 2q23.1 deletions and those with intragenic MBD5 rearrangements, including alterations confined entirely to the 5 0 -untranslated region, confirming the critical impact of non-coding sequence at this locus. We identified heterogeneous, multisystem pathogenic effects of MBD5 disruption and characterized the associated spectrum of psychopathology, including the novel finding of anxiety and bipolar disorder in multiple patients. Importantly, one of the unique features of the oldest known patient was behavioral regression. Analyses also revealed phenotypes that distinguish MBD5 disruptions from seven well-established syndromes with significant diagnostic overlap. This study demonstrates that haploinsufficiency of MBD5 causes diverse phenotypes, yields insight into the spectrum of resulting neurodevelopmental and behavioral psychopathology and provides clinical context for interpretation of MBD5 structural variations. Empirical evidence also indicates that disruption of non-coding MBD5 regulatory regions is sufficient for clinical manifestation, highlighting the limitations of exon-focused assessments. These results suggest an ongoing perturbation of neurological function throughout the lifespan, including risks for neurobehavioral regression.
INTRODUCTION
The increasing resolution of genomic technologies, including cytogenomic microarrays and next-generation sequencing, has led to remarkable advances in our understanding of the highly heterogeneous genetic etiology of neurodevelopmental conditions such as autism spectrum disorders (ASD). Among the largest known genetic risk factors contributing to ASD are recurrent structural variations such as chromosomal microdeletions and microduplications. However, interpretation of the associated clinical outcomes is complicated by the varying sizes of these dosage imbalances, which typically disrupt many genes. For example, the 16p11.2 microdeletion and microduplication syndromes are associated with a spectrum of features, including ASD, schizophrenia, obesity, dysmorphic characteristics and numerous other neuropsychiatric and behavioral disorders. 1, 2 Only a small number of recurrent chromosomal microdeletion syndromes have a single known contributing gene, such as SATB2 in 2q33.1 3, 4 and EHMT1 in 9q34.3, to name just two. 4, 5 The localization of these contributing loci provides a route to understanding pathogenic mechanisms as well as deeply characterizing associated phenotypic features of these typically heterogeneous and complex syndromes. In this study, we perform extensive phenotypic analyses of the diverse psychopathology associated with a single necessary and sufficient causal locus in the chromosome 2q23.1 microdeletion syndrome and describe the clinical features that overlap with multiple known syndromes.
The pathogenesis of 2q23.1 microdeletion syndrome was recently defined by Talkowski et al. 6 and others [7] [8] [9] [10] [11] [12] [13] [14] [15] to be due to a single gene, MBD5 (methyl-CpG-binding domain protein 5) , through characterization of the minimal region of overlap from non-recurrent genomic alterations in a cohort of 65 cases with chromosomal deletions or translocations. The mRNA isoform 1 of MBD5 comprises 15 exons, with exons 1-5 forming the nontranslated 5 0 -untranslated region (UTR). Monoallelic expression of this locus was found to be highly penetrant as both partial and complete deletions of MBD5 involving coding and/or nontranslated exons resulted in diverse neurodevelopmental phenotypes, including ASD, intellectual disability and seizures. In addition, no disruptive alterations of MBD5 exons were observed in 7,878 controls or in the reportedly phenotypically normal individuals in the Database of Genomic Variants. 6 All deletions of MBD5 in the Database of Genomic Variants were smaller than 3 kb and confined to intronic sequences, mostly in the non-coding 5 0 -UTR. Further confirmation of the dosage-sensitive nature of MBD5 was found in three cases of reciprocal 2q23.1 duplication, which manifest intellectual disability, autistic features, developmental delay and other phenotypes. 16, 17 The association of MBD5 disruption with ASD and other neurobehavioral features is supported by its expression in the brain and the suggested function of its methyl-CpG-binding domain in heterochromatin and epigenetic regulation. 18, 19 In addition, sequencing of the MBD5 coding region identified a missense mutation (p.79Gly4Glu) in this functionally critical domain that was significantly over-represented in 747 ASD patients compared with 2,043 individuals from an exomesequencing study of patients with disorders of the heart, lungs and blood (NHLBI Exome Sequencing Project; initial P ¼ 0.012, odds ratio (OR) ¼ 5.5). 6 Notably, the recent completion and revised variant calling in the final exome-sequencing analyses of this mutation provides a more robust estimate of its association and effect size in ASD (P ¼ 0.0039, OR ¼ 5.2). 20 The methyl-CpGbinding domain is also shared with MECP2, a causal locus for Rett syndrome. Clinical features associated with MBD5 deletions have considerable overlap with Rett syndrome and can also masquerade as Smith-Magenis (SMS), Cornelia de Lange (CdLS), Angelman (AS), Prader-Willi (PWS), Kleefstra and Pitt-Hopkins (PTHS) syndromes.
We report here phenotypic characterization of 22 individuals with MBD5 structural alterations collected through a multiinstitution collaboration, revealing a complex clinical syndrome that involves a diverse range of neurodevelopmental features with variable severity. A significant inclusion in this cohort is the oldest known MBD5 deletion patient who provides important confirmatory evidence that behavioral regression is a potential outcome. Interestingly, a subset of these patients with disruptions confined to the non-coding region of MBD5 manifest a similar spectrum of clinical features as those with coding region rearrangements, confirming a pathogenic role for non-coding regulatory domains. We further identified considerable phenotypic overlap between MBD5 disruptions and other known diagnoses, and provide clinical context for syndrome differentiation, with an emphasis on neurobehavioral considerations.
PATIENTS AND METHODS Subjects
Diagnostic screening of postnatal peripheral blood specimens from 17,477 consecutive patients tested in the Mayo Clinic Cytogenetics Laboratory from 2008 to 2012, using either the 4 Â 44K or 4 Â 180K oligonucleotidebased whole-genome cytogenomic microarray (Agilent Technologies, Santa Clara, CA, USA), identified eight deletions spanning genomic segments including MBD5 (Cases 1-8). Six of these cases were of sufficient size for detection (4100 kb) and had cells available for confirmation by fluorescence in situ hybridization, while the remaining two cases were confirmed using an Affymetrix Cytoscan HD Array (Affymetrix, Santa Clara, CA, USA). Clinical phenotypic information was obtained from medical records following a Mayo Clinic IRB-approved protocol. A multi-institution collaboration of clinical diagnostic laboratories resulted in inclusion of additional patients not previously published from the Greenwood Genetic Center (Cases 9-12 (Noh/Case 19) , as well as an intragenic frameshift mutation c.150del or p.Thr52Hisfs*31 described by Kleefstra et al. 5 (Kleefstra/Case 20) and an intragenic indel of À TC at position 148,942,435 in hg18 of exon 9 described by O'Roak et al. 23 (O'Roak/Case 21), all of which were published after the Talkowski et al. study. 6 The final patient, DGAP235 (Case 22), was enrolled in the Developmental Genome Anatomy Project (DGAP; www.dgap.harvard.edu) based on karyotypic detection of a de novo, balanced translocation 46,XY,t(2;5)(q22;q22), which was found to disrupt MBD5 by massively parallel paired-end sequencing; this case was independent of two previously published translocations targeting MBD5. 6 For all of the deletion cases in the new cohort, the genomic coordinates of the deleted regions, both minimum (that is, the region encompassing known deleted probes) and maximum (that is, the region extending to the first flanking probes of known normal copy number), as well as the array platforms and method of deletion validation are presented in Supplementary Table S1 .
Genetic analysis of translocation case
Whole-genome sequencing was performed using large-insert fragments in a mate-pair method that was previously optimized and applied to cases with abnormal karyotypes. 4, 24, 25 Paired-end sequencing of fragments separated by 2000 bases in genomic distance enabled high coverage of mapped inserts in a genome-wide manner with minimal individual nucleotide coverage required. In brief, genomic DNA was randomly sheared and size selected for 2 kb fragments. A cap adaptor containing an EcoP15I restriction site was ligated to the fragment ends and circularized with an internal adaptor containing a subject-specific bar code and a single biotinylated thymine. The circularized fragments were restriction digested, junction fragments were isolated by binding the biotinylated adaptor to streptavidin beads and an Illumina library was prepared directly on the beads. Multiplexed paired-end 25 cycle sequencing was performed on an Illumina HiSeq 2000 and 45.7% of all reads corresponded to DGAP235 (87,079,316 read pairs). Quality control was assessed using FASTQC (Babraham Bioinformatics, Cambridge, UK) followed by distributed parallel alignment of FASTQ read data to the human genome reference hg19 using BWA 0.5.9, 26 merging of aligned BAM files with SAMtools 0.1.18 26 and coordinate and name-sorting of aligned read pairs using Picard Tools 1.5.8 (http://picard.sourceforge.net). A single-linkage clustering of anomalous read pairs was competed with subsequent filtering of clusters based on size, mapping quality, uniqueness and presence in a previous database of whole-genome sequencing samples from a neurodevelopmental cohort 4 using a custom pipeline developed in C þþ (BamStat, developed in ME Talkowski's Lab, Boston, MA, USA) and MATLAB (Mathworks, Natick, MA, USA). The average mapped insert was 1,862 bp (s.d. ¼ 332 bp) and 94.1% of all reads aligned, yielding an average coverage of mappable inserts of approximately 39.2X. See Supplementary Figure S1 and Table S2 as well as the Supplementary Results for library metrics, alignment information and bioinformatics analysis.
Phenotypic analysis
The developmental history and neurological, behavioral and physical characteristics of the new patients were assembled. In addition, the original phenotypic data from the 65 cases reported by Talkowski et al. 6 were examined. Each case with detailed phenotypic information was assessed through a genetics consult. The compiled data were then reviewed by a single clinical geneticist with follow-up questions to the original contributors when possible. Microcephaly was defined in the Talkowski et al. cases 6 as o3rd percentile or 2 s.d. below the mean, while the new patients were distinguished by a head circumference below the 5th percentile. Age-dependent characteristics were considered relative to developmental stage. Individuals were categorized as autistic or autisticlike when specifically reported by collaborators as having 'autism' or 'autism-like behaviors', when evaluated with Autism Diagnostic Observation Schedule (ADOS) or Autism Diagnostic Interview -Revised (ADI-R), or when given a diagnosis of pervasive developmental disorder (PDD-NOS). Phenotypic features were classified as present, absent or not evaluated, and were reported in Table 3 only if present in more than one individual.
The clinical features of the new cohort (n ¼ 22) were assessed for both overlap with and divergence from those cases in the published original cohort that had phenotypic data available (n ¼ 48) to enable a more comprehensive phenotypic profile associated with MBD5 disruption. A list of the 48 cases analyzed from the original cohort of Talkowski et al. 6 is provided in the Supplementary Results. The phenotypic spectrum of the combined original and new MBD5 disruptions (n ¼ 70) was then compared and contrasted to well-established syndromes with diagnostic overlap (SMS, CdLS, AS, PWS, Rett, Kleefstra and PTHS). In each of these evaluations, cases were grouped by genotype, that is, intragenic MBD5 disruptions versus overlapping 2q23.1 deletions.
RESULTS

Identification and molecular characterization of MBD5 disruption cases
The frequency of MBD5 deletion was estimated to be 0.05% based on the identification of 8 cases out of 17 477 consecutive Mayo Clinic peripheral blood samples submitted for clinical testing by cytogenomic microarray. These 8 deletions, along with 10 cases from collaborators and 4 cases identified recently in the literature, define a new cohort that is independent of the subjects in Talkowski et al. 6 The new cohort (n ¼ 22) includes one frameshift mutation, one indel mutation, one inverted translocation directly disrupting MBD5, three intragenic MBD5 deletions and 16 larger deletions. The rearrangements arose de novo in all cases for which parental testing was available (n ¼ 11). However, two cases without parental genetic or phenotypic information involve brothers with similar deletions (Cases 9 and 10), suggesting likely parental inheritance or gonadal mosaicism. No bias in gender or age of diagnosis was observed in the 13 male and 9 female subjects ranging in age from 2 weeks to 44 years.
The disrupted region varied from a single base pair point mutation to a 5.4 Mb microdeletion, with 17 of the alterations being no more than 1.1 Mb (Figure 1a ). Five of these alterations are within MBD5, and all but one of which is confined entirely to the non-coding 5 0 -UTR. The maximum deleted region in each deletion case of the new cohort (Cases 1-19) does not affect any coding region of additional genes or alter whether an intragenic MBD5 deletion is confined to the non-coding 5 0 -UTR or coding region when compared with the minimum deleted region (Supplementary Table S1 ). The only exception is Case 8, in which the deletion involving the 5 0 -UTR of LYPD6B may also affect the first coding exon, although this is of questionable importance because LYPD6B is a provisional gene. In addition, Case 2 is a high percentage mosaic with the deletion present in 28/30 metaphases and 77.5% of interphase nuclei from a cultured specimen, as well as 81.0% of interphase nuclei from a direct preparation.
No other CNVs of known clinical significance were identified in any of the MBD5 region deletion cases in the new cohort. Only two cases had additional CNVs of unknown clinical significance that met reporting criteria: a deletion of uncertain inheritance at chromosome 22q11.21 in Case 6 (genomic coordinates 19,062,437-19,835,417 in hg18; 773 kb; 20 genes) and a de novo deletion from chromosome 5q11.2 to 5q12.2 in Case 11 (genomic coordinates 58,401,783-63,433,812 in hg18; 5 MB; 14 genes). Although the 22q CNV is at the telomeric end of the recurrent 22q11.2 deletion/duplication syndrome critical region, studies have suggested that the classic features of this syndrome are likely the result of mutations affecting dosage of TBX1, 27,28 a gene not included in the present 22q deletion CNV. Analysis of patients with similar distal 22q11.2 deletions not including TBX1 did not find a consistent phenotype. 29 In addition, no information regarding a phenotype definitively associated with heterozygous deletion of any of the specific genes in either the 22q or 5q CNVs disrupted in these patients has been established, although clinical significance cannot be ruled out. Indeed, as the Girirajan et al. 30 paper
hypothesizes that the presence of a second large CNV occurs more frequently in patients whose primary CNV is associated with a phenotypically variable genomic disorder when compared with syndromic genomic disorders, these co-occurring CNVs could result in additive or epistatic effects on neurodevelopmental pathways, possibly through disruption of genes in the second-site variant that interact with those in the primary variant. 30 Case 22 harbored a de novo translocation between chromosomes 2 and 5 that was balanced at karyotypic resolution. Wholegenome sequencing by large-insert jumping libraries revealed direct disruption of MBD5 at the breakpoint on chromosome 2. The orientation of a small subset of reads relative to the reference sequence also supported the presence of a small local inversion at the chromosome 5 breakpoint on the der(2) chromosome, suggesting a translocation with an accompanying inversion (Figure 1b) . We previously discovered that such microinversions are a pervasive feature of karyotypically balanced translocations. 24 Capillary sequencing confirmed the translocation breakpoints on both derivative chromosomes and the presence of an 169 bp microinversion of chromosome 5 on the der(2). The chromosome 2 breakpoints (der(2):148,732,432; der(5):148,733,228 in human genome build hg18) directly disrupt the 5 0 non-coding region of MBD5 that was previously shown to be interrupted in two independent translocations sequenced in Talkowski et al. 6 In sum, a total genomic imbalance of 795 bp was observed at the der(5) breakpoint (including both deleted sequence and duplication of microhomology), and the der(2) translocation and inversion events resulted in 41 bp of deleted sequence. The chromosome 5 breakpoint occurred in an intergenic region without annotated coding sequence within a 500 kb window of the breakpoint. Sequencing thus revised the interpretation of the karyotype from 46,XY,t(2;5)(q22;q22) to 46,XY,der(2)t(2;5)(q23.1;q23.1)inv(5)(q23. 1q23.1),der(5)t(2;5)(q23.1;q23.1)dn. See Supplementary Table S3 for complete breakpoint information.
In the original cohort described by Talkowski et al. 6 there were 12 intragenic MBD5 deletions, two other translocations disrupting the same untranslated region of MBD5 as the present case, and 41 larger 2q23.1 microdeletions encompassing MBD5 and additional genes ranging in size from 38 kb to 19.3 Mb. After removal of the Talkowski et al. 6 cases without phenotypic information, the remaining 48 individuals were added to the 22 new cases for analysis. This combined cohort (n ¼ 70) involved three translocations, one point mutation, one indel and 65 deletions; 16 are intragenic MBD5 alterations, all but one of which are confined to the 5 0 -UTR. The following analyses are derived from the phenotypic features of these 70 individuals.
MBD5 disruption is associated with neurodevelopmental features and clinical variation including behavioral regression
Comparison of the original raw data from the MBD5 disruption cases in Talkowski et al. 6 to a new cohort of 22 cases demonstrated an independent confirmation of substantial genetic and phenotype overlap between the two groups. Combined assessment of these cohorts showed that MBD5 disruption has a multisystem effect leading to behavioral, growth/endocrine, craniofacial, skeletal, gastrointestinal, heart, urogenital and central nervous system anomalies. To define specifically a core phenotype associated with MBD5 disruption, the common features replicated across the Talkowski et al. cohort and the new cohort were identified. Phenotypes reported in X50% of cases with at least four affected patients in each of the two cohorts include autistic-like behaviors, distractibility/short attention span, self-injurious behaviors including skin and eye picking, sleep disturbances, ataxia/unusual gait, developmental delay/intellectual disability, hypotonia/abnormal muscle tone, motor delay, seizures, speech delay, short stature, microcephaly, nasal abnormalities, outer ear abnormalities, downturned mouth corners or everted lower lip, tented upper lip, thin upper lip, fifth finger clinodactyly, small hands or feet and constipation ( Table 1) .
The phenotypes are largely indistinguishable between intragenic MBD5 and larger deletions, whether considering neurodevelopmental and behavioral abnormalities specifically or all other features (Table 1) . However, a small subset of the characteristics may have resulted from loss of neighboring genes. This is suggested by features that were confined to larger deletion cases in both the new cohort and separately in the original cohort 6 that were assessed in at least four patients, specifically bruxism, hyperphagia, ataxia, obesity, brachycephaly, metopic ridging, optic nerve hypoplasia, strabismus, coarse facies, wide mouth, brachydactyly and hypoplastic genitalia. It is of note that only 2 of (Table 1) . However, definitive genotype/phenotype correlations are challenging because of the relative rarity of intragenic MBD5 disruptions (n ¼ 16) compared with 2q23.1 microdeletions (n ¼ 54), warranting further consideration in even larger cohorts. The possibility also exists that some features in Table 1 are coincidental and unrelated to disruption of the 2q23.1 region. Potential novel behavioral features linked with MBD5 disruption are suggested in the new cohort including anxiety and bipolar disorder, which are present in two or more patients, in addition to sensory integration disorder and self-hugging as well as a number of physical anomalies ( Table 2 ). The associations of MBD5 disruption with optic nerve hypoplasia and with social withdrawal were also potentially confirmed through observation of a second affected patient (Case 3 and Case 21, respectively). The new cohort further includes the oldest known MBD5 disruption patient (Case 3), a 44-year-old man who demonstrated behavioral regression with worsening skin picking and obsessive-compulsive tendencies, which eventually improved with medication. Regression of motor and verbal skills was also noted in a second case in the new cohort (Case 19). 22 Phenotypic presentation of MBD5 disruption overlaps with known syndromes We analyzed extensive phenotypic data in a large cohort of subjects with MBD5 disruptions to understand the consequences of multiple mutational mechanisms impacting transcription of this gene and to provide an assessment algorithm for clinicians to identify affected patients. However, devising an appropriate testing strategy presents a significant challenge because of substantial heterogeneity in both the type and severity of MBD5-related phenotypes, which span cognitive, behavioral and physical domains. Moreover, MBD5 disruption is a potent masquerader, resulting in a number of clinical features previously thought to be unique to other syndromes. On the basis of our analyses, it is clear that a first-tier diagnostic cytogenomic microarray test will aid in the partitioning of subjects into genespecific disorders characterized by dosage imbalance. Such a recommendation would be consistent with recent guidelines. 31, 32 Absence of detectable dosage imbalance will then require clinicians to decide if karyotype or targeted gene-specific testing, such as sequencing for intragenic point mutations, small deletions or duplications, is appropriate based on the phenotypic gestalt. Of note, although whole-exome sequencing is moving towards replacing cytogenomic arrays and gene or gene panel sequencing, targeted gene analysis could still have an important role in the future as UTR variants, including those in multiple cases in this study, might not otherwise be detected.
To aid in determining the next diagnostic step in the absence of a detectable dosage imbalance, we present expansion of the clinical heterogeneity associated with MBD5 disruption, as well as the distinguishing phenotypes or constellations of anomalies which would suggest additional diagnostic testing for MBD5 versus targeting a classic syndrome with overlapping features, including SMS, [33] [34] [35] [36] [37] [38] PWS, [39] [40] [41] [42] [43] [44] AS, 45, 46 CdLS, [47] [48] [49] [50] Rett, [51] [52] [53] Kleefstra, [54] [55] [56] or PTHS. [57] [58] [59] Thus, the phenotypes in the combined cohort separated by intragenic MBD5 versus larger 2q23.1 deletions that occurred in two or more cases were compared with those of other syndromes considered in the differential diagnosis (Table 3) .
Neurodevelopmental and behavioral characteristics common to all of these syndromes include autistic-like actions, intellectual Each denominator is the total cases for which the feature was specifically documented as being present or absent during a clinical assessment. disability, developmental delay, speech delay, motor delay, hypotonia, sleep disturbances and seizures. There are also features confined solely to each of the syndromes in the differential diagnosis as detailed in the Supplementary Results. Although single characteristics can be helpful, the phenotypic diversity noted with MBD5 disruptions remains a diagnostic challenge, as illustrated in the divergence of facial dysmorphism in MBD5 deletion cases, ranging from isolated ear anomalies to multiple atypical characteristics (Figure 2) . A clear understanding of how the breadth of phenotypes compares and contrasts for these multiple diagnoses is required. The differentiating and overlapping neurodevelopmental, behavioral and other features presented in Table 3 are further described in detail for each syndrome in the Supplementary Results.
DISCUSSION
Deletions encompassing MBD5 are highly penetrant and result in a broad phenotypic spectrum that includes many neurodevelopmental and psychiatric traits. Our analyses of 22 cases with extensive clinical information confirm the phenotypes previously described in an independent cohort of 65 subjects described in Talkowski et al. 6 and define the significant psychopathology associated with MBD5 disruptions. When combined, these data demonstrate similar phenotypic traits between individuals with intragenic MBD5 alterations and larger 2q23.1 microdeletions, consistent with MBD5 being the necessary and sufficient pathogenic target in 2q23.1 microdeletion syndrome. The new cohort further expands the potential phenotypic spectrum to include the behavioral characteristics of sensory integration disorder, anxiety, bipolar disorder and self-hugging, as well as the physical anomalies polydactyly, skin tags, diaphragmatic eventration, ventricular septal defect, spina bifida, cutis marmorata, flat occiput and short neck. The associations with optic nerve hypoplasia and with social withdrawal, each observed in a single patient in the original cohort, 6 were also demonstrated by independent cases in this new cohort.
The potential for MBD5 to perturb neurological function throughout life was demonstrated by the oldest known subject harboring a deletion of MBD5 (Case 3, 44 years). Such a delayed diagnosis is consistent with the difficulty in clinically identifying MBD5 deletions based solely on phenotype without diagnostic genetic data and suggests potential longevity for affected individuals. The psychiatric diagnosis of the 44-year-old patient included obsessive-compulsive disorder, bipolar disorder with severe psychotic features and behavioral regression with a significant increase in skin picking and obsessive-compulsive activities. This individual thus represents the third case for which regression has been documented. Regression also occurred in a second patient included within the new cohort (Noh/Case 19), a 2-year-old girl with a 300 kb deletion overlapping two genes at 2q23.1. This child walked independently at 28 months of age, but an examination at 4 years showed that she had lost a subset of her vocabulary and the ability to walk, standing only with support. 22 Another case of developmental regression was previously noted to occur suddenly at 6 years of age in a girl with a de novo approximately 4 Mb deletion involving 15 genes at 2q23.1-q23.3. This child had progressive difficulties with fine motor skills and balance, worsening behavior and loss of the ability to draw lines and circles. 9 It is of note that this child was originally tested for Rett and Angelman syndromes with normal results before the MBD5 deletion was identified. These results merit careful evaluation of future cases for developmental and behavioral regression and emphasize the recommendation of cytogenomic microrarray as a first-tier test for all such cases.
Many features found in MBD5 deletions, such as intellectual disability, motor and speech delays, sleep disturbances, microcephaly and seizures, are nonspecific and commonly found in multiple genetic syndromes. A more specific spectrum of behavioral and other phenotypes in individuals with MBD5 disruptions may be diagnostically useful, although it remains challenging to differentiate from the profiles in other syndromes including SMS, CdLS, AS, PWS, Rett, Kleefstra and PTHS. In fact, many patients with MBD5 deletions previously reported in the literature were referred for genetic testing for one or more of Although no parental testing has been performed, Cases 9 and 10 are siblings, indicating that the deletion is likely inherited. 
these disorders, all of whom were negative, before cytogenomic microarray provided an accurate diagnosis; this is illustrated well in a study of 2q23.1 microdeletion syndrome patients (n ¼ 11) who had normal test results for AS (n ¼ 8), SMS (n ¼ 5) and Rett (n ¼ 4) syndrome. 8 In the present cohort, the known additional testing included karyotype (n ¼ 6), fragile X analysis (n ¼ 6), RAI1 sequencing for SMS (n ¼ 2), MECP2 and CDKL5 sequencing for Rett syndrome (n ¼ 1), methylation analysis and UBE3A sequencing for PWS/AS (n ¼ 1) and TCF4 sequencing for PTHS (n ¼ 1). It is of note that guidelines indicate fragile X testing should be performed for any patient with intellectual disability, 60 a feature also found in MBD5 disruption, although there is no overlap of more specific phenotypes between these two syndromes which suggests that they should be clinically distinguishable.
The ability of MBD5 deletions to manifest significant clinical heterogeneity that overlaps with previously defined syndromes in a highly penetrant manner confirms the advantage of using unbiased, high-resolution genome-wide surveys such as cytogenomic microarrays when any of the above-mentioned syndromes is suspected. However, cytogenomic microarrays do not detect balanced abnormalities or small pathogenic mutations, as occurred in Cases 20-22, suggesting that implementation of whole-genome sequencing will also have a significant diagnostic impact and karyotyping may reveal additional balanced rearrangements. Our results further raise important issues about the current interpretation of variants of unknown significance and coding region-focused analyses such as exome sequencing as we found highly penetrant pathogenic rearrangements confined to the putative 5 0 -UTR of MBD5 (as in Cases 5, 6, 16, 20 and 22) to be 
contributory towards diverse phenotypes. Therefore, a focused phenotypic annotation was undertaken in this study to complement the recent genetic characterization 6 of MBD5 disruptions and to identify features that contrast with syndromes for which MBD5 can be mistaken. This may help determine an appropriate testing strategy and avoid unnecessary medical expenses.
In summary, these data confirm that genetic alterations of MBD5 represent highly penetrant risk factors for neurodevelopmental and other abnormalities. We extend the associated clinical heterogeneity to a broad range of neuropsychiatric features including anxiety and bipolar disorder, provide a differential diagnostic context and suggest that this locus is potentially associated with risk for neurobehavioral regression. Future studies focusing on further careful phenotyping across the lifespan to understand the potential contributions of genetic modifiers and environmental influences on the variable expressivity of MBD5 disruptionassociated features will be invaluable for further defining the impact of MBD5 alterations on human psychopathology. 
